Celcuity Inc. (CELC)

Market Cap	568.29M
Revenue (ttm)	n/a
Net Income (ttm)	-73.45M
Shares Out	35.10M
EPS (ttm)	-2.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	335,339
Open	16.65
Previous Close	16.64
Day's Range	16.09 - 16.65
52-Week Range	8.39 - 22.19
Beta	0.85
Analysts	Strong Buy
Price Target	29.25 (+80.67%)
Earnings Date	Aug 8, 2024

About CELC

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: CELC

Analyst Forecast

According to 4 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price forecast is $29.25, which is an increase of 80.67% from the latest price.

Price Target

$29.25

(80.67% upside)

Analyst Consensus: Strong Buy